LX2006's registrational SUNRISE-FA 2 readout will determine whether Breakthrough-designated AAV gene therapy reaches BLA submission for Friedreich ataxia cardiomyopathy

Bull

A positive outcome would show ≥15% improvement in LVMI versus untreated controls at the 6-month topline readout, replicating and extending the 18-23% LVMI improvement seen in Phase I/II, with a favorable safety profile and no new complement activation signals. This would validate FDA's openness to pooling Phase I/II data with pivotal data, enabling a H1 2028 BLA submission and positioning LX2006 as the first approved gene therapy for Friedreich ataxia cardiomyopathy.

Bear

The most likely failure modes are an effect size that falls below the ≥15% LVMI threshold in the small 13-vs-13 controlled cohort — where the study has limited statistical power — or emergence of safety signals such as clinically significant complement activation or immune-mediated hepatotoxicity at commercial-scale Sf9-baculovirus manufacturing that were not observed in Phase I/II. High placebo-effect or regression-to-the-mean in the natural history control arm could also compress the treatment difference and cause the primary endpoint to miss.